{"news": [{"date": "20240327234800", "headline": "Merck: EC approves Keytruda plus chemotherapy to treat NSCLC", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240328000600", "headline": "PDS Biotechnology price target lowered to $5 from $16 at Alliance Global Partners", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240328002300", "headline": "Japan Index Falls While Asia And Europe Markets Rise, And Gold Exceeds $2,220 - Global Markets Today While US Slept", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240328004500", "headline": "The Reserve Bank Of South Africa Kept The Rate At 8.25%", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240328020000", "headline": "Merck price target raised by $3 at Truist, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240328034100", "headline": "MRK May 10th Options Begin Trading", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240328040256", "headline": "Merck: new indication approved for Keytruda in Europe", "summary": "Merck announced on Thursday that the European Commission has granted marketing authorization for Keytruda, its blockbuster immunotherapy, in the treatment of operable non-small cell lung cancer at..."}, {"date": "20240328044500", "headline": "European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults", "summary": "RAHWAY, N.J., March 28, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck\u2019s anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adults."}, {"date": "20240328045700", "headline": "Pfizer, Astellas first-line bladder cancer therapy accepted for review in China", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240328051500", "headline": "Company News for Mar 28, 2024", "summary": "Companies In The News Are: HOOD, COIN, MRK, NCNO."}, {"date": "20240328071500", "headline": "How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together", "summary": "Two Merck leaders share how their company is working to help protect communities from vaccine-preventable illnesses NORTHAMPTON, MA / ACCESSWIRE / March 28, 2024 / Vaccines are one of the most significant public health achievements in modern history, ..."}, {"date": "20240328074007", "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick", "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage."}, {"date": "20240328155019", "headline": "Merck (MRK) Rises Higher Than Market: Key Facts", "summary": "Merck (MRK) reachead $131.95 at the closing of the latest trading day, reflecting a +0.15% change compared to its last close."}, {"date": "20240328200800", "headline": "Buy Rating on Merck & Co. Affirmed by Daina Graybosch Amidst WINREVAIR\u2019s Market Potential and Efficacy", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240329070020", "headline": "Merck & Co., Inc.'s (NYSE:MRK) Intrinsic Value Is Potentially 98% Above Its Share Price", "summary": "Key Insights Using the 2 Stage Free Cash Flow to Equity, Merck fair value estimate is US$261 Merck is estimated to be..."}, {"date": "20240329085129", "headline": "3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List", "summary": "As the number of grey-haired people rises worldwide, investors need to notice the strong-buy healthcare stocks. The need for healthcare will grow as the number of people aged 60 years and older doubles by 2050, a situation never before witnessed in the world, thanks to smaller families and longer lifespans. All of this is great for strong buy healthcare stocks as they can target a huge addressable market. U.S. healthcare spending is estimated to reach a total market value of about $6.2 trillion"}, {"date": "20240330051500", "headline": "Eli Lilly tops S&P 500 healthcare sector in Q1 as weight loss frenzy continues", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240330224902", "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of March 31", "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here for the complete list for the week of March 31."}, {"date": "20240331213600", "headline": "Merck & Co. Inc. stock underperforms Monday when compared to competitors", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240401020500", "headline": "Expert Ratings For Merck & Co", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240401034900", "headline": "The least shorted S&P 500 stocks as a percentage of float - BofA", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240401044500", "headline": "Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25", "summary": "RAHWAY, N.J., April 01, 2024--Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25"}, {"date": "20240401075011", "headline": "Why Merck (MRK) is a Top Momentum Stock for the Long-Term", "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage."}, {"date": "20240401191000", "headline": "Russell 2000 Index Best And Worst Performing Stocks Of 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240401212600", "headline": "Cantor Fitzgerald Remains a Buy on Merck & Company (MRK)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240402103937", "headline": "Merck: Better Times Ahead On Approvals And Outlook", "summary": "Merck & Co., Inc.'s stock price is up 20% YTD, supported by approvals, a positive outlook for 2024. Check out why I\u00e2\u0080\u0099m going with a buy rating for MRK stock."}, {"date": "20240403011200", "headline": "Daiichi Sankyo, Merck announe first patient dosed in REJOICE-Ovarian01 trial", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240403030000", "headline": "Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade)", "summary": "Analyst cautiousness regarding MRK's outperformance amid Keytruda's success and acquisitions, with a suggestion to wait for a pullback in stock price. Read more here."}, {"date": "20240403034226", "headline": "Merck: 1st patient in raludotatug study", "summary": "Merck and its partner Daiichi Sankyo announced today that the first patient has received a dose in a phase 2/3 trial evaluating the efficacy and safety of the investigational raludotatug deruxtecan ..."}, {"date": "20240403041300", "headline": "Daiichi, Merck announce first patient dosed in ovarian cancer trial", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240403060000", "headline": "REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer", "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer"}, {"date": "20240403061000", "headline": "Bristol Myers wins label expansion for anemia therapy in EU", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240403083346", "headline": "3 Dow Jones Stocks For Your April 2024 Watch List", "summary": "Here are 3 Dow Jones stocks to watch in the stock market today."}, {"date": "20240403155019", "headline": "Merck (MRK) Stock Sinks As Market Gains: What You Should Know", "summary": "Merck (MRK) reachead $129.90 at the closing of the latest trading day, reflecting a -0.35% change compared to its last close."}, {"date": "20240403234900", "headline": "Merck initiates Phase 3 clinical trial of MK-1084", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240404013000", "headline": "Merck starts phase 3 MK-1084 trial for lung cancer treatment", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240404013200", "headline": "Merck to test lung cancer combo therapy in late-stage trial", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240404023301", "headline": "Merck: launches phase III trial in lung cancer", "summary": "Merck announced today that it has launched a phase 3 clinical trial evaluating its ' MK-1084 ' in combination with Keytruda for the first-line treatment of selected patients with metastatic non-small..."}, {"date": "20240404044500", "headline": "Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer", "summary": "RAHWAY, N.J., April 04, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1 (tumor proportion score [TPS] \u226550%)."}, {"date": "20240404051100", "headline": "Piper Sandler pharmaceuticals analysts hold an analyst/industry conference call", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240404053800", "headline": "Merck puts KRAS cancer drug competitor to the test", "summary": "A Phase 3 study will compare Merck\u2019s experimental KRAS inhibitor together with its immunotherapy Keytruda against Keytruda alone in\u00a0lung cancer."}, {"date": "20240405035650", "headline": "Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer", "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C..."}, {"date": "20240405051600", "headline": "Merck & Company (MRK) Receives a Buy from Cantor Fitzgerald", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240405054711", "headline": "BME: Trading At A Historical Discount To NAV", "summary": "BlackRock Health Sciences Trust offers 6.35% dividend yield & discounted NAV, providing an opportunity to benefit from healthcare sector growth. Learn more on BME CEF here."}, {"date": "20240405154519", "headline": "Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing", "summary": "Merck (MRK) concluded the recent trading session at $127.99, signifying a +0.26% move from its prior day's close."}, {"date": "20240406070116", "headline": "The three-year decline in earnings for Merck NYSE:MRK) isn't encouraging, but shareholders are still up 93% over that period", "summary": "By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with..."}, {"date": "20240406184753", "headline": "10 Best Weight Loss Drug Stocks to Buy Now", "summary": "In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it\u2019s one of the biggest trends on the stock market right now, then you can take a look at the [\u2026]"}, {"date": "20240406191400", "headline": "Citi's top recommended large-cap stocks", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240407063300", "headline": "Morgan Stanley sees Fed rate cut fueling biotech stock performance", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240407063900", "headline": "Morgan Stanley sees Fed rate cut fueling biotech stocks", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240407120000", "headline": "The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024", "summary": "Looking ahead, the future of the U.S. economy appears promising despite ongoing challenges. President Biden\u2019s efforts to steer the economy through inflation concerns are showing strong results. Recent data indicates a healthy economic position, with significant GDP growth outpacing other developed nations. Despite fluctuations in inflation and interest rates, the U.S. labor market remains resilient, adding jobs at a rapid pace. The country\u2019s economic resilience, bolstered by substantial fiscal s"}, {"date": "20240407194300", "headline": "Moderna Stock (NASDAQ:MRNA): This mRNA Tech Pioneer Has Rebound Potential", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240407224300", "headline": "Merck price target raised to $146 from $140 at Berenberg", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240408030700", "headline": "Merck price target raised by $3 at Berenberg, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240408120000", "headline": "Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement", "summary": "Most people consider retirement one of the most important events to prepare for. Focusing on long-term investments, preferably with strong dividend yields, is a great way to get started. With compounding interest and dividend growth, investors who take investing and saving for retirement seriously can become very profitable over a number of decades. Here are a number of stocks that provide investors with a fantastic start to a long-term investment portfolio for growth as well as overall income g"}, {"date": "20240408234933", "headline": "Upcoming Catalysts Position Perrigo For Sustained Long-Term Dividend Growth", "summary": "Perrigo is poised to turn the corner under the leadership of a new CEO who is only nine months in the seat. Read why I rate PRGO stock a buy now."}, {"date": "20240409042800", "headline": "Moderna stock climbs 8% amid head/neck cancer vaccine data", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409194700", "headline": "Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410035300", "headline": "The Pharmaceutical Industry Finds Itself At A Historical Crossroads", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410041100", "headline": "MRK December 2026 Options Begin Trading", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410072500", "headline": "Company News for Apr 10, 2024", "summary": "Companies in The News Are: MRNA, MRK, COIN, BN, NEOG"}, {"date": "20240410085900", "headline": "Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study", "summary": "Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer."}, {"date": "20240410193500", "headline": "See Which Of The Latest 13F Filers Holds Merck & Co", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411025200", "headline": "The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411033900", "headline": "Cardinal Health, Cigna, Merck among top healthcare Quant picks ahead of Q1 earnings", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411042500", "headline": "Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411080048", "headline": "Merck & Co., Inc.'s (NYSE:MRK) Stock Financial Prospects Look Bleak: Should Shareholders Be Prepared For A Share Price Correction?", "summary": "Merck's (NYSE:MRK) stock is up by 7.0% over the past three months. However, its weak financial performance indicators..."}, {"date": "20240411220700", "headline": "Merck & Company: Balancing Growth Prospects Against Rising Operational Challenges", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412012900", "headline": "GLOBAL BROKER RATINGS: JPMorgan raises Persimmon, BoA raises Nike", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412020100", "headline": "Biogen Is Suffering From Doubts About the Future", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412044000", "headline": "7 A-Rated Aggressive Biotech Stocks to Bet On in 2024", "summary": "The best biotech stocks to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. Regulatory hurdles make finding biotech stocks to buy challenging if you don\u2019t have the patience to wait it out. But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That\u2019s why it\u2019s a good idea to at least consider biotech, and whether they have a spot in your portfolio.InvestorPla"}, {"date": "20240415034600", "headline": "Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415054858", "headline": "10 Best Low Volatility ETFs To Buy", "summary": "In this article, we discuss 10 best low volatility ETFs to buy. If you want to skip our discussion on low volatility investments, head over to 5 Best Low Volatility ETFs To Buy. What is Low Volatility Investing? Low volatility investing refers to an investment strategy where a stock portfolio is less volatile in terms [\u2026]"}, {"date": "20240416020000", "headline": "MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416052800", "headline": "As more rare disease therapies launch, their prices are rising", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416102442", "headline": "FHLC: Healthcare Dashboard For April", "summary": "Fidelity MSCI\u00c2\u00a0Health Care\u00c2\u00a0Index ETF is an alternative to XLV for long-term investors. Read this article to learn more about FHLC ETF."}, {"date": "20240416131708", "headline": "3 Dow Stocks to Buy Now: Q2 Edition", "summary": "Let\u2019s be real \u2013 the narrative for Dow stocks to buy now tends to be one of relative safety. What are the chances that the 30 companies of the Dow Jones Industrial Average will be the most exciting ideas of any given year? I\u2019d say quite low. However, circumstances can always change, as we\u2019ve seen in the geopolitical environment. Following Iran launching missiles against Israel in retaliation for allegedly bombing its embassy in Syria, the world is on edge regarding Israel\u2019s likely response. What"}, {"date": "20240416212200", "headline": "Market Whales and Their Recent Bets on MRK Options", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417020000", "headline": "MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417023000", "headline": "GreensKeeper Value Fund Q1 2024 Letter", "summary": "GKAM's Value Fund finished Q1 2024 +10.1% net of fees and expenses, with the USD as a headwind. Click here to read the full letter. "}, {"date": "20240417035846", "headline": "Merck Manuals Celebrates Its 125th Year", "summary": "RAHWAY - When searching for authoritative medical information online, it's reassuring to know that Merck Manuals is committed to providing an experience void of advertising or sponsored content of..."}, {"date": "20240417050040", "headline": "Merck Insiders Sold US$15m Of Shares Suggesting Hesitancy", "summary": "The fact that multiple Merck & Co., Inc. ( NYSE:MRK ) insiders offloaded a considerable amount of shares over the past..."}, {"date": "20240417060000", "headline": "Coming FDA Approvals Could Send These 3 Drug Stocks Soaring", "summary": "In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA approval for a drug or treatment can bring years or even decades of steady, high-margin revenue. This is why investors who specifically look to target drug stocks are always aware of an upcoming FDA catalyst for that company. FDA approvals are bullish whether the company is a pre-revenue startup or a global pharmaceutical giant. At the same time, FDA rejections can tank a drug s"}, {"date": "20240417095202", "headline": "Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To", "summary": "Merck is set to announce Q1 earnings next week. Read why Merck's future looks promising, despite its looming Keytruda patent expiry. Learn more on MRK stock here."}, {"date": "20240417190400", "headline": "Unveiling 17 Analyst Insights On Merck & Co", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418001800", "headline": "Marks Electrical Secures New Lease Agreement", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418014600", "headline": "Marks Electric agrees extension of headquarters' lease in Leicester", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418052600", "headline": "Cantor Fitzgerald Reaffirms Their Buy Rating on Merck & Company (MRK)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418142703", "headline": "13 Best Low Volatility Stocks to Buy According to Hedge Funds", "summary": "In this article, we discuss the 13 best low volatility stocks to buy according to hedge funds. To skip the detailed analysis of the current market conditions, go directly to the 5 Best Low Volatility Stocks to Buy According to Hedge Funds. The S&P 500 had a remarkable year in 2023 and the first quarter [\u2026]"}, {"date": "20240418200200", "headline": "Catalyst Watch: Tesla, Boeing and General Motors brace for earnings fireworks", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240419010348", "headline": "Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth", "summary": "Pfizer announced positive results from a pivotal clinical trial evaluating Abrysvo's efficacy against respiratory syncytial virus. See why PFE stock is a Buy."}, {"date": "20240419050400", "headline": "Health Canada Approves KEYTRUDA\u00ae as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy", "summary": "Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA\u00ae (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This approval is based on the results from the Phase 3 KEYNOTE-859 trial, whic"}, {"date": "20240419050800", "headline": "Merck garners Canadian approval for Keytruda in first-line gastroesophageal cancer", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240419074943", "headline": "Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout", "summary": ""}, {"date": "20240420060300", "headline": "THQ: Collecting A High Yield From Increased Medical Spending", "summary": "abrdn Healthcare Opportunities Fund (THQ) offers a high dividend yield and exposure to diverse healthcare subsectors, outperforming peers. Explore more here."}, {"date": "20240420194400", "headline": "Goldman picks top capex and R&D stocks", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240420224900", "headline": "Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240421004642", "headline": "Wall Street Breakfast: The Week Ahead", "summary": "Stay updated with the latest financial news and market trends by listening to the Wall Street Breakfast podcast available on Seeking Alpha, iTunes, and..."}, {"date": "20240421010500", "headline": "Earnings week ahead: Tesla, Meta Platforms, Google, Microsoft, Intel, Exxon Mobil, and more", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240421050033", "headline": "Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 78%", "summary": "Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their..."}, {"date": "20240421054300", "headline": "3 Under-The-Radar Stocks With Positive Potential", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240421212600", "headline": "Top high growth investment ratio stocks from each sector - GS", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422000200", "headline": "Options Volatility and Implied Earnings Moves This Week, April 22 \u2013 April 26, 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422082023", "headline": "Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts", "summary": "Hookipa Pharma's positive data could push shares up 3-5x while negative news could cut the stock in half or worse. Check out more on HOOK stock here."}, {"date": "20240422091059", "headline": "10 Best Performing Biotech ETFs in 2024", "summary": "In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for [\u2026]"}, {"date": "20240422123900", "headline": "How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?", "summary": "Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings."}, {"date": "20240423020100", "headline": "Takeda Pharmaceutical: A Long-Term Cash Cow", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240423024800", "headline": "Looking Into Merck & Co's Recent Short Interest", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240423030003", "headline": "Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?", "summary": "Gilead Sciences will report its Q1 2024 earnings on Thursday, April 25. Check out whether GILD stock is a good buy ahead of Q1 earnings."}, {"date": "20240423033000", "headline": "Baron Health Care Fund Q1 2024 Shareholder Letter", "summary": "In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared with the 8.52% gain for the Russell 3000 Health Care Index and the 10.56% gain for the S&P 500 Index."}, {"date": "20240423054516", "headline": "ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle", "summary": "ImmunityBio has financial resources for the short-term, but long-term financial health remains uncertain. Click here to read my IBRX update."}, {"date": "20240423054928", "headline": "Here\u2019s Why Merck & Co. (MRK) Outperformed in Q1", "summary": "Baron Funds, an investment management company, released its \u201cBaron Health Care Fund\u201d first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P [\u2026]"}, {"date": "20240423064036", "headline": "ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications", "summary": "ImmunityBio finally received FDA approval for its drug ANKTIVA for the treatment of patients with BCG-unresponsive NMIBC with CIS. Read more on IBRX stock here."}, {"date": "20240423130000", "headline": "3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge", "summary": "Big money tends to flow from one sector to the other. During the pandemic, sectors like pharmaceutical and e-commerce were hot. This was followed by major buying interest in electric vehicles and other energy transition themes. When money flows out from one sector, it generally translates into undervaluation. This seems to be the case with pharmaceutical stocks. During the covid-19 pandemic, the pharma sector witnessed big buying and valuations looked stretched. In the post pandemic world, the s"}, {"date": "20240423151138", "headline": "Investor Alert: Prepare for the Market Crash With These 3 Stocks", "summary": "As an investor with significant positions in equities, I am an optimist. However, it\u2019s important to be realistic at the same time. This helps in readjusting the portfolio depending on macroeconomic, geopolitical, and other headwinds. In my view, potential delay in rate cuts is likely to make the market nervous as it might imply a hard landing for the economy. I would therefore look at stocks to buy for a market crash. I must however add that I see the first-rate cut coming before the Presidentia"}, {"date": "20240423211300", "headline": "Immutep reports promising efti/Keytruda data for head and neck cancer", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424012500", "headline": "Notable companies reporting before tomorrow's open", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424030700", "headline": "Merck Q1 Earnings Preview: Strong quarter expectations on the back of core products' growth", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424080900", "headline": "4 Large Drug Stocks to Hold on to Amid Industry Challenges", "summary": "Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio."}, {"date": "20240424155048", "headline": "Alphabet, Microsoft, Southwest earnings: What to watch", "summary": "Here are some of the biggest stories investors will be watching on Thursday, April 25, 2024. A slew of companies will report their quarterly results including Microsoft (MSFT), Alphabet (GOOG, GOOGL), and Southwest Airlines (LUV). On the economic data front, the highly anticipated preliminary read on first quarter GDP will be released. Economists are expecting that the US economy grew by 2.2% in the first three months of the year. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith"}, {"date": "20240424200300", "headline": "Marks Electrical CFO Rebalances Share Portfolio", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424201000", "headline": "Merck price target raised by $1 at Truist, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424213000", "headline": "What You Missed On Wall Street On Thursday", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424214000", "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424225100", "headline": "Analysts Conflicted on These Healthcare Names: Travere Therapeutics (TVTX), Humana (HUM) and Merck & Company (MRK)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424230100", "headline": "APA Corp Leads Smead Value Fund's Q1 2024 Portfolio Adjustments with 0.68% Impact", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424232300", "headline": "US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424233100", "headline": "Merck reports Q1 adjusted EPS $2.07, consensus $1.87", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424233200", "headline": "Merck raises FY24 adjusted EPS view to $8.53-$8.65 from $8.44-$8.59", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424233400", "headline": "Merck\u2019s first-quarter results beat expectations amid healthy vaccine-sales growth", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424233800", "headline": "Merck Non-GAAP EPS of $2.07 beats by $0.15, revenue of $15.8B beats by $600M", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425000300", "headline": "Merck in charts: Pharmaceutical segment soars on KEYTRUDA, GARDASIL strength in Q1", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425000600", "headline": "Options Volatility and Implied Earnings Moves Today, April 25, 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425001400", "headline": "Merck raises guidance as Keytruda sales jump 20% in Q1", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425004300", "headline": "MRK Earnings: Merck Delivers Q1 Earnings Beat", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425004500", "headline": "Merck KGaA lays cornerstone for research centre in Darmstadt", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425004515", "headline": "Merck: Q1 Earnings Snapshot", "summary": "RAHWAY, N.J. \u2014 RAHWAY, N.J. \u2014 Merck & Co. on Thursday reported first-quarter earnings of $4.76 billion. On a per-share basis, the Rahway, New Jersey-based company said it had profit of..."}, {"date": "20240425010100", "headline": "Bristol-Myers posts Q1 beat despite growth headwinds", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425011300", "headline": "Merck & Co raises annual outlook thanks to first quarter boost", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425015300", "headline": "Fly Intel: Pre-market Movers", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425015740", "headline": "Merck raises annual target ranges", "summary": "On the occasion of the publication of its quarterly results, Merck announces that it has raised and tightened its target ranges for adjusted EPS and revenues for the full year 2024, expecting them..."}, {"date": "20240425035700", "headline": "Meta Falls 15% On Great Earnings, Tesla Rises 12% On Ugly Earnings \u2013 Here Is The Real Reason", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425035900", "headline": "MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q1 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425043000", "headline": "Merck raises 2024 profit forecast on strong cancer, HPV drugs sales", "summary": "Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda and human papillomavirus (HPV) vaccine Gardasil.  The New Jersey-based drugmaker said it expected earnings of $8.53 and $8.65 per share, up from its previous prediction of $8.44 to $8.59, and sales of $63.1-$64.3 billion for the year.  Merck's new forecast includes a $0.26 per share charge for its $680 million acquisition of cancer drug developer Harpoon Therapeutics, which closed in the first quarter of 2024, the company said."}, {"date": "20240425043000", "headline": "Merck Announces First-Quarter 2024 Financial Results", "summary": "RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results"}, {"date": "20240425043303", "headline": "Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda", "summary": "(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of strong sales for its blockbuster cancer drug Keytruda, sending the company's shares up more than 2% before the bell.  Keytruda, the world's top selling drug in 2023, has been Merck's key revenue driver over the past few years and is expected to top $30 billion in sales by 2026 before losing exclusivity toward the end of the decade.  The drug is seeing growth from use for additional types of cancers as well as higher patient demand, Chief Financial Officer Caroline Litchfield said."}, {"date": "20240425050418", "headline": "UPDATE 3-Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda", "summary": "Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of double-digit growth for its blockbuster cancer drug Keytruda, the world's top selling prescription medicine.  Merck forecast 2024 sales between $63.1 billion and $64.3 billion, up from its previous view of $62.7 billion to $64.2 billion.  Analysts are estimating sales of $63.83 billion."}, {"date": "20240425051000", "headline": "What You Missed On Wall Street This Morning", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425051000", "headline": "S&P 500 Down Over 1%; Merck Increases 2024 Outlook", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425063800", "headline": "Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425070017", "headline": "We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt", "summary": "Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to..."}, {"date": "20240425071300", "headline": "Merck Stock Climbs After Higher-Than-Expected Sales of Cancer Drug Keytruda", "summary": "Shares of U.S. drugmaker Merck are up nearly 4% in recent trading after the company said its blockbuster cancer drug Keytruda fueled a higher-than-expected increase in quarterly sales and earnings.  Merck also raised and narrowed its forecast range for full-year sales and earnings.  Sales of Keytruda, the world\u2019s top-selling drug, rose 20% to $6.9 billion for the first quarter."}, {"date": "20240425071300", "headline": "Merck Shares Climb After Higher-Than-Expected Sales of Cancer Drug Keytruda", "summary": "Shares of U.S. drugmaker Merck are up nearly 4% in recent trading after the company said its blockbuster cancer drug Keytruda fueled a higher-than-expected increase in quarterly sales and earnings.  Merck also raised and narrowed its forecast range for full-year sales and earnings.  Sales of Keytruda, the world\u2019s top-selling drug, rose 20% to $6.9 billion for the first quarter."}, {"date": "20240425081529", "headline": "Merck & Co., Inc. (MRK) Q1 2024 Earnings Call Transcript", "summary": "Merck &amp; Co., Inc. (NYSE:NYSE:MRK) Q1 2024 Results Conference Call April 25, 2024 9:00 AM ETCompany ParticipantsPeter Dannenbaum - SVP, IRRob Davis -..."}, {"date": "20240425092333", "headline": "Merck raises 2024 guidance on cancer drug demand", "summary": "Shares of Merck & Company (MRK) are trading higher early Thursday after the pharmaceutical giant posted robust sales results in the first quarter, leading the pharmaceutical giant to raise its 2024 outlook. The company's performance was driven by strong demand for its cancer drug Keytruda. Yahoo Finance's Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance. This post was written by Angel Smith"}, {"date": "20240425093424", "headline": "20 Fastest Growing Health Tech Companies in the World", "summary": "In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital [\u2026]"}, {"date": "20240425094204", "headline": "Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma", "summary": "Bristol-Myers Squibb\u2019s market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club.  After reporting disappointing earnings figures on Thursday, the company\u2019s shares fell sharply, giving it a market capitalization of about $95 billion.  The problem for Bristol-Myers is that its older blockbuster products, cancer drug Revlimid and blood thinner Eliquis, are expected to decline in the coming years and investors aren\u2019t convinced that the company has enough growth drivers in the near term."}, {"date": "20240425100900", "headline": "Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales", "summary": "Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market."}, {"date": "20240425114916", "headline": "These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)", "summary": "The Annual Meeting of ASCO is a major event for clinicians and researchers in the field of oncology. Explore more details here."}, {"date": "20240425122901", "headline": "Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook", "summary": "On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck\u2019s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck\u2019s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me"}, {"date": "20240425133012", "headline": "Merck (MRK) Q1 2024 Earnings Call Transcript", "summary": "MRK earnings call for the period ending March 31, 2024."}, {"date": "20240425200400", "headline": "Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425214900", "headline": "Merck & Company (MRK) Gets a Buy from Barclays", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425233100", "headline": "Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Globus Medical (GMED) and Merck & Company (MRK)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426002600", "headline": "Merck & Co. Outperforms with Strong Keytruda Sales and Raised Guidance: A Buy Rating Affirmed", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426011700", "headline": "Merck & Company: A Strong Buy on Robust Performance and Future Growth Prospects", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426012000", "headline": "Merck price target raised by $5 at Wells Fargo, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426022600", "headline": "Merck price target raised by $15 at BofA, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426041500", "headline": "Interesting MRK Put And Call Options For June 7th", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426095640", "headline": "Diving Into Deciphera Pharmaceuticals", "summary": "Deciphera's Vimseltinib is expected to make significant progress in the TGCT indication. Check out my\u00c2\u00a0investment analysis around DCPH stock here."}, {"date": "20240427062447", "headline": "Merck & Co., Inc. (NYSE:MRK) Just Released Its First-Quarter Earnings: Here's What Analysts Think", "summary": "Merck & Co., Inc. ( NYSE:MRK ) just released its quarterly report and things are looking bullish. The company beat..."}, {"date": "20240427210000", "headline": "Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429003213", "headline": "TECB: Not A Good Choice When Compared To Other Traditional Technology ETFs", "summary": "TECB has generally outperformed the S&P 500 in bull markets but underperformed in bear markets since its inception in 2020. See why the Fund is a Hold."}, {"date": "20240429020100", "headline": "Novo Nordisk: Growth Is Still A Better Choice", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429032300", "headline": "Merck late-stage data strengthens profile of pneumonia vaccine candidate", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429065600", "headline": "Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429070000", "headline": "Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults", "summary": "RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults"}, {"date": "20240429190700", "headline": "Buy Rating Affirmed on Merck & Company Following Strong Q1 Performance and Upbeat Full-Year Guidance", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430031400", "headline": "FTC expands patent listing challenges for drugs", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430064422", "headline": "Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript", "summary": "Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.07, expectations were $1.94. Merck & Co., Inc. isn\u2019t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank [\u2026]"}, {"date": "20240501003900", "headline": "Merck: KEYNOTE-811 trial meets dual primary endpoint of OS", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501011200", "headline": "GLOBAL BROKER RATINGS: Bernstein raises Deutsche Lufthansa", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501015300", "headline": "Merck Keytruda combo meets main goal in late-stage trial for advanced gastric cancer", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501020100", "headline": "Novartis Is Tracking Well Above the Industry", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501051500", "headline": "Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma", "summary": "RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer"}, {"date": "20240501084105", "headline": "Eli Lilly Shoots Higher: It's Time To Be Cautious", "summary": "If we see shares continue to climb like this, a downgrade for Eli Lilly and Company stock could be on the horizon. Learn why we rate LLY stock a hold."}, {"date": "20240501165200", "headline": "15 Best Places to Retire in Florida That You\u2019ve Never Heard Of", "summary": "This article takes a look at the 15 best places to retire in Florida that you\u2019ve never heard of. If you wish to skip our detailed analysis of financial challenges and hidden gems in Florida, you may go to the 5 Best Places to Retire in Florida That You\u2019ve Never Heard Of. Navigating Financial Challenges [\u2026]"}, {"date": "20240501211500", "headline": "Janux Therapeutics gains amid renewed takeover speculation", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502050236", "headline": "Merck: encouraging results in gastric cancer", "summary": "Merck announced today that the phase 3 trial evaluating Keytruda in combination with trastuzumab, fluoropyrimidine and platinum-based chemotherapy has met its dual primary endpoint of overall..."}, {"date": "20240502054500", "headline": "Cerevance receives milestone payment under Alzheimer's collaboration with Merck", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502064100", "headline": "10 Health Care Stocks Whale Activity In Today's Session", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502125354", "headline": "Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration", "summary": "After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc (NASDAQ: MRNA) in fighting melanoma. Merck reported improvement in cancer patients receiving its Keytruda regimen. Enrolling 698 subjects, the trial evaluated the effect of a treatment that combines Merck\u2019s immunotherapy blockb"}, {"date": "20240503022800", "headline": "Job Market Cools In April: Payrolls Miss Forecasts, Wages Rise Less Than Expected (UPDATED)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503050200", "headline": "Vanguard Health Care Fund's Strategic Moves in Q1 2024: A Focus on Pfizer Inc", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503050200", "headline": "MRK June 14th Options Begin Trading", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503075012", "headline": "Here's Why Merck (MRK) is a Strong Momentum Stock", "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service."}, {"date": "20240503213935", "headline": "SCHD: A Must-Have In Every Dividend Portfolio", "summary": "Schwab U.S. Dividend Equity ETF (SCHD) offers diversification and resilience with a focus on healthy dividend-paying companies, but lower total returns. Read more here."}]}